KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesChange in Working CapitalExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to $2.3 billion.

  • Novartis Ag's Cash from Operations fell 4600.52% to $2.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $19.1 billion, marking a year-over-year increase of 865.54%. This contributed to the annual value of $19.1 billion for FY2025, which is 865.54% up from last year.
  • Novartis Ag's Cash from Operations amounted to $2.3 billion in Q4 2025, which was down 4600.52% from $6.6 billion recorded in Q3 2025.
  • In the past 5 years, Novartis Ag's Cash from Operations ranged from a high of $6.7 billion in Q2 2025 and a low of $1.6 billion during Q1 2022
  • Moreover, its 5-year median value for Cash from Operations was $3.8 billion (2021), whereas its average is $4.0 billion.
  • As far as peak fluctuations go, Novartis Ag's Cash from Operations skyrocketed by 7932.08% in 2023, and later crashed by 4600.52% in 2025.
  • Quarter analysis of 5 years shows Novartis Ag's Cash from Operations stood at $3.9 billion in 2021, then decreased by 2.99% to $3.8 billion in 2022, then crashed by 32.4% to $2.5 billion in 2023, then soared by 64.63% to $4.2 billion in 2024, then plummeted by 46.01% to $2.3 billion in 2025.
  • Its Cash from Operations stands at $2.3 billion for Q4 2025, versus $6.6 billion for Q3 2025 and $6.7 billion for Q2 2025.